NLSP (NLS Pharmaceutics Ltd.) רווח נקי למניה (EPS TTM)

NLS Pharmaceutics AG focuses on sleep disorder therapies utilizing a network of specialized centers. The trailing twelve-month EPS dynamics on GURU.Markets reflect this trajectory, where the 52.20 metric indicates the current value. The company's prospects rely on the regulation of circadian rhythms, while final risks depend on clinical test results and regulatory approval timelines.
NLSP (NLS Pharma): פילוחים אנליטיים ודוחות לפי אינדיקטורים

The market evaluates NLS Pharmaceutics AG (NLSP) through the lens of capital management efficiency within a high-risk sector. This indicator measures the dynamics of earnings per share over a rolling year, comparing current results with historical data. By analyzing the annual EPS TTM growth measurement, an investor sees the value 52.20, which reflects the business monetization rates. The growth of this metric confirms the profitability of the strict logistics for narcolepsy treatments. The stability of this trend guarantees the resilience of the company's fundamental value.